Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non‐small cell lung cancer
British Journal of Pharmacology2023Vol. 181(8), pp. 1221–1237
Citations Over TimeTop 20% of 2023 papers
Yufei Chen, Yan‐Chun Pang, Han‐Chen Wang, Pei‐En Wu, Zi‐Jie Chen, Da Huang, Dong‐Ling Peng, Yong‐Ming Yan, Changhui Liu, Lichuan Wu, Xiangzhen Fan, Yong‐Xian Cheng, Yongqiang Liu
Abstract
ArC suppressed DNA cross-linking drug-induced DNA damage response by inhibiting the mTOR/E2F1/FANCD2 signalling axis, serving as a chemosensitizing agent. This provides insight into the anticancer mechanisms of ArC and offers a potential combinatorial anticancer therapeutic strategy.
Related Papers
- → Ouabain, a Cardiac Glycoside, Inhibits the Fanconi Anemia/BRCA Pathway Activated by DNA Interstrand Cross-Linking Agents(2013)24 cited
- → Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines(2007)25 cited
- → Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation(2019)12 cited
- → Planispine A Sensitized Cancer Cells to Cisplatin by Inhibiting the Fanconi Anemia Pathway(2022)2 cited
- Progress of research in tumor chemosensitizer(2006)